Achieve Life Sciences (ACHV) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $6.97, -0.43% vs the prior close of $7.00.
- Volume 1.20M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ACHV dips 0.4% to $6.97, a 1-month low, 4 down days in a row. Closed at $6.97, -0.43% vs the prior close of $7.00. Day range $6.83–$7.13, opened at $7.00.
ACHV daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ACHV dips 0.4% to $6.97, a 1-month low, 4 down days in a row
- Closed at $6.97, -0.43% vs the prior close of $7.00. Day range $6.83–$7.13, opened at $7.00.
- Volume was 1.20M shares, 0.8x its 50-day average of 1.50M.
- Price is -8.1% vs its 50-day average ($7.58) and +25.3% vs its 200-day average ($5.56).
- 52-week range $2.62–$8.64; today's close sits at 72% of that range, 19.3% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — ACHV ends flat (+0.0%) to $7.00, 3 down days in a row
- Closed at $7.00, +0.00% vs the prior close of $7.00. Day range $6.83–$7.11, opened at $6.98.
- Volume was 1.64M shares, 1.1x its 50-day average of 1.49M.
- Price is -7.6% vs its 50-day average ($7.57) and +26.1% vs its 200-day average ($5.55).
- 52-week range $2.62–$8.64; today's close sits at 73% of that range, 19.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ACHV dips 0.8% to $7.00, a 1-month low
- Closed at $7.00, -0.85% vs the prior close of $7.06. Day range $6.92–$7.20, opened at $7.00.
- Volume was 1.65M shares, 1.1x its 50-day average of 1.47M.
- Price is -7.5% vs its 50-day average ($7.56) and +26.4% vs its 200-day average ($5.54).
- 52-week range $2.62–$8.64; today's close sits at 73% of that range, 19.0% below the 52-week high.
Oct 12, 2026 — ACHV slides 4.7% to $7.06
- Closed at $7.06, -4.72% vs the prior close of $7.41. Day range $7.05–$7.45, opened at $7.39.
- Volume was 948.70K shares, 0.6x its 50-day average of 1.48M.
- Price is -6.5% vs its 50-day average ($7.55) and +27.8% vs its 200-day average ($5.53).
- 52-week range $2.62–$8.64; today's close sits at 74% of that range, 18.3% below the 52-week high.
Oct 9, 2026 — ACHV jumps 3.1% to $7.41
- Closed at $7.41, +3.06% vs the prior close of $7.19. Day range $7.14–$7.48, opened at $7.20.
- Volume was 987.30K shares, 0.7x its 50-day average of 1.47M.
- Price is -1.7% vs its 50-day average ($7.54) and +34.4% vs its 200-day average ($5.51).
- 52-week range $2.62–$8.64; today's close sits at 80% of that range, 14.2% below the 52-week high.
Oct 8, 2026 — ACHV dips 0.7% to $7.19
- Closed at $7.19, -0.69% vs the prior close of $7.24. Day range $7.05–$7.32, opened at $7.14.
- Volume was 1.11M shares, 0.8x its 50-day average of 1.48M.
- Price is -4.3% vs its 50-day average ($7.52) and +30.8% vs its 200-day average ($5.50).
- 52-week range $2.62–$8.64; today's close sits at 76% of that range, 16.8% below the 52-week high.
Oct 7, 2026 — ACHV rises 3.0% to $7.24
- Closed at $7.24, +2.99% vs the prior close of $7.03. Day range $6.96–$7.35, opened at $7.02.
- Volume was 1.04M shares, 0.7x its 50-day average of 1.48M.
- Price is -3.4% vs its 50-day average ($7.49) and +32.0% vs its 200-day average ($5.48).
- 52-week range $2.62–$8.64; today's close sits at 77% of that range, 16.2% below the 52-week high.
Oct 6, 2026 — ACHV ends flat (+0.3%) to $7.03
- Closed at $7.03, +0.29% vs the prior close of $7.01. Day range $6.89–$7.23, opened at $7.06.
- Volume was 1.06M shares, 0.7x its 50-day average of 1.48M.
- Price is -5.9% vs its 50-day average ($7.47) and +28.6% vs its 200-day average ($5.47).
- 52-week range $2.62–$8.64; today's close sits at 73% of that range, 18.6% below the 52-week high.
Oct 5, 2026 — ACHV slides 3.2% to $7.01, a 1-month low, 3 down days in a row
- Closed at $7.01, -3.18% vs the prior close of $7.24. Day range $6.83–$7.34, opened at $7.24.
- Volume was 1.70M shares, 1.2x its 50-day average of 1.47M.
- Price is -6.0% vs its 50-day average ($7.46) and +28.5% vs its 200-day average ($5.45).
- 52-week range $2.62–$8.64; today's close sits at 73% of that range, 18.9% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — ACHV slides 3.9% to $7.24
- Closed at $7.24, -3.85% vs the prior close of $7.53. Day range $7.05–$7.63, opened at $7.62.
- Volume was 1.89M shares, 1.3x its 50-day average of 1.45M.
- Price is -2.7% vs its 50-day average ($7.44) and +33.1% vs its 200-day average ($5.44).
- 52-week range $2.62–$8.64; today's close sits at 77% of that range, 16.2% below the 52-week high.
ACHV latest news & SEC filings
Every SEC filing by or about ACHV in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 6, 2026 · 3 — Initial insider ownership statement (Form 3)
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Oct 1, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 21, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Stewart Richard Alistair sold 20,626 shares at $8.49 (≈$175.11K) on Aug 19, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 19, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 17, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 13, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$74.77M (prior year -$12.72M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.80 (prior year -$0.37) (loss widened vs Jun 30, 2025)
Aug 11, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 28, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ACHV
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 24, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.28% (largest 6.9%).
- Liquidity: about 1.42M shares (≈$9.92M) trade per day on average.
- 52-week position: $6.97 vs a range of $2.62–$8.64 (72% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 1 sales; latest: Richard Alistair Stewart sold 20,626 shares on Aug 19, 2026.
- Latest filings: 8-K Oct 1, 2026; 8-K Aug 14, 2026; 10-Q Aug 11, 2026.
- Share count: 102.90M shares outstanding (Aug 11, 2026), +101.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: In Vitro & In Vivo Diagnostic Substances.
ACHV market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 7.00 | 7.13 | 6.83 | 6.97 | 1.20M |
| Oct 14, 2026 | 6.98 | 7.11 | 6.83 | 7.00 | 1.64M |
| Oct 13, 2026 | 7.00 | 7.20 | 6.92 | 7.00 | 1.65M |
| Oct 12, 2026 | 7.39 | 7.45 | 7.05 | 7.06 | 948.70K |
| Oct 9, 2026 | 7.20 | 7.48 | 7.14 | 7.41 | 987.30K |
| Oct 8, 2026 | 7.14 | 7.32 | 7.05 | 7.19 | 1.11M |
| Oct 7, 2026 | 7.02 | 7.35 | 6.96 | 7.24 | 1.04M |
| Oct 6, 2026 | 7.06 | 7.23 | 6.89 | 7.03 | 1.06M |
| Oct 5, 2026 | 7.24 | 7.34 | 6.83 | 7.01 | 1.70M |
| Oct 2, 2026 | 7.62 | 7.63 | 7.05 | 7.24 | 1.89M |
| Oct 1, 2026 | 7.89 | 8.04 | 7.52 | 7.53 | 1.15M |
| Sep 30, 2026 | 8.08 | 8.28 | 7.87 | 8.09 | 2.38M |
| Sep 29, 2026 | 7.75 | 7.76 | 7.47 | 7.69 | 1.03M |
| Sep 28, 2026 | 7.50 | 7.84 | 7.35 | 7.75 | 1.30M |
| Sep 25, 2026 | 7.90 | 7.96 | 7.51 | 7.54 | 1.42M |
| Sep 24, 2026 | 7.79 | 8.14 | 7.62 | 7.83 | 1.14M |
| Sep 23, 2026 | 8.15 | 8.20 | 7.76 | 7.83 | 1.33M |
| Sep 22, 2026 | 8.15 | 8.42 | 7.95 | 8.12 | 1.67M |
| Sep 21, 2026 | 8.03 | 8.07 | 7.82 | 8.05 | 1.01M |
| Sep 18, 2026 | 7.91 | 8.09 | 7.80 | 7.98 | 2.83M |
About Achieve Life Sciences
Achieve Life Sciences (ACHV) is listed on the Nasdaq and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in SEATTLE, WA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 949858.
ACHV board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeffrey S Farrow | Director | Jul 29, 2026 |
| Andrew D. Goldberg | CEO and President | Apr 21, 2026 |
| Lucian Iancovici | Director | Apr 24, 2026 |
| Christopher Nathan Martin | Director | Jul 29, 2026 |
| Nancy R. Phelan | Director | Jul 29, 2026 |
| Aaron Royston | Director | Jul 29, 2026 |
| Thomas Sellig | Director | Jul 29, 2026 |
| Richard Alistair Stewart | Director | Aug 21, 2026 |
| Reid Alexander Waldman | Director | Jul 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Erik Atkisson | Chief Legal Officer | Dec 8, 2025 |
| Craig Donnelly | Chief Operations Officer | Jan 30, 2026 |
| Andrew D. Goldberg | CEO and President | Apr 21, 2026 |
| Mark K Oki | Chief Financial Officer | Jan 30, 2026 |
| Mark Lawrence Rubinstein | Chief Medical Officer | Jan 30, 2026 |
| Jerry Wan | Principal Accounting Officer | Jan 30, 2026 |
| Jaime Xinos | Chief Commercial Officer | Jan 30, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Richard Alistair Stewart | Sale | 20,626 | $8.49 |
ACHV financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-54.65M | -1.25 | $-49.47M |
| Dec 31, 2024 | — | $-39.83M | -1.24 | $-29.77M |
| Dec 31, 2023 | — | $-29.82M | -1.50 | $-24.48M |
| Dec 31, 2022 | — | $-42.35M | -4.00 | $-37.57M |
| Dec 31, 2021 | — | $-33.15M | -4.08 | $-29.44M |
Latest balance sheet: total assets $190.44M, total liabilities $205.12M, cash $47.96M (as of Jun 30, 2026).
ACHV earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $6.77 |
| May 12, 2026 | 8-K Item 2.02 (results) | $5.99 |
| Mar 24, 2026 | 8-K Item 2.02 (results) | $2.90 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $4.74 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $2.64 |
| May 13, 2025 | 8-K Item 2.02 (results) | $2.65 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $2.92 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $5.00 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 28, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories (IDXX)Lantheus (LNTH)Intellia Therapeutics (NTLA)Neogen (NEOG)Celldex Therapeutics (CLDX)QuidelOrtho (QDEL)Myriad Genetics (MYGN)Alpha Teknova (TKNO)Insight Molecular Diagnostics (IMDX)Volitionrx (VNRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ACHV
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.